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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not proton 
pump inhibitors are a safe and effective treatment for gastroesophageal reflux disease in infants 
less than twelve months old. 
STUDY DESIGN: Review of three English language primary studies published in 2003, 2007, 
2009 
DA TA SOURCES: Randomized, double blind, placebo controlled trials comparing proton pump 
inhibitors to placebo were found using Ovid MEDLINE, and Cochrane databases. 
OUTCOMES MEASURED: Gastroesophageal reflux disease symptoms in infants. Symptoms 
include crying, irritability, vomiting, apnea, bradycardia, choking, and behavioral trials. One 
trial used responder status, which is defined as a 2:50% reduction from baseline in either 
percentages of feedings with crying episodes or duration (in minutes) of episodes averaged 
across feedings. Another trial documented the cry/fuss time in minutes per 24 hour period. 
Other outcomes include adverse events requiring treatment and serious adverse events requiring 
hospitalization. 
RESULTS: All three RCTs included in this review found that proton pump inhibitors were not 
effective in reducing the symptoms of GERD in infants. There was no significant decrease 
compared to control groups. One RCT showed a significant increase in the number of both 
adverse events and serious adverse events compared to placebo groups. 
CONCLUSIONS: Results of the RCTs reviewed demonstrate that proton pump inhibitors are 
not a safe and effective treatment for gastroesophageal reflux disease in infants less than twelve 
months old. Further research is warranted to determine the primary cause ofthese reflux 
symptoms and to investigate transient lower esophageal sphincter relaxation. 
KEY WORDS: proton pump inhibitors, inf~mts 
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INTRODUCTION 
Gastroesophageal reflux disease (GERD) is a common disorder affecting persons of all 
ages and is characterized by reflux of the gastric contents into the esophagus, causing 
complications. Many infants under the age of one, including premature infants, experience 
symptoms attributed to GERD. The principal treatment for symptomatic GERD in adults and 
children is acid suppression. Proton pump inhibitors (PPI) have widespread use in adults and 
children and are recognized as the most effective agents to suppress gastric acid secretion 2. 
Although FDA indication for PPT use does not include patients less than one year old, there has 
recently been an increasing amount of PPIs used for this age group to alleviate symptoms l . 
GERD in infants is of major relevance to the scope of physician assistant practice. 
Excessive crying is the most common reason for parents to seek medical help for newborns in 
the first three months of life 2. It is hypothesized that gastroesophageal reflux is a frequent cause 
of this irritability and crying. While GERD is usually a benign process in infants, significant 
irritability of the child leads to increased concern of the parent and more frequent medical visits 
and costs. If the irritability of the infant is related to reflux, then reduction in acid exposure by 
highly effective proton pump inhibitors should reduce the symptoms. This logical hypothesis 
has been put into practice, as demonstrated by the seven-fold increase in the use PPIs in infants 
between 1999 and 2004 1• Because there is no FDA indication for PPI use in infants, the actual 
amount of money spent on "off-label" use ofPPIs for this population is not well-documented or 
readily available. 
GERD is defined as symptoms or mucosal damage produced by the abnormal ret1ux of 
gastric contents into the esophagus. The clinical symptoms of GERD in an infant differ from 
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symptoms of an adult. The most common symptom of GERD in an infant is 
regurgitation/vomiting 4. The additional symptoms in an infant are non-specific and include 
excessive irritability and crying, failure to thrive, feed refusal, apnea, or aspiration pneumonia. 
Preterm infants and newborns are at increased risk for GERD due to their immature musculature, 
predominantly liquid diet and supine positioning while feeding. The principal mechanism of 
acid reflux in infants is found to be transient lower esophageal sphincter relaxation3. Moreover, 
GERD in infants is associated with the development of serious chronic health issues such as 
recurrent pneumonia, chronic cough, recurrent stridor and reactive airway disease 4. 
The goals of therapy for GERD are to relieve symptoms, promote healing of esophagus, 
and to prevent respiratory complications and recurrence of the disease. Treatment ofGERD in 
children and adults includes antacids, pro-kinetic agents, and acid suppressants, such has 
histamine H2 receptors and PPIs. Currently there are no therapies that target the transient 
relaxation of the lower esophageal sphincter. In children over the age of one it has been found 
that PPIs have superior efficacy over other treatments4• Because no PPIs are approved for usage 
in infants, conservative treatments and non-pharmacological management are attempted initially. 
Feeding strategies include the use ofthickened or hypoallergenic formulas, frequent burping, 
frequent small feedings, or dairy avoidance by breast-feeding. Because there is an increase in 
reflux when supine, parents are encouraged to try to minimize supine positioning and vigorous 
handling post-feeding. Additional simple conservative measures include increased parental 
reassurance and smoking cessation I. 
While the above treatments may be efiective, many infants do not respond to 
conservative treatments. PPIs may provide satisfactory reduction of symptoms of GERD in 
infants over other products and methods. Based on the findings that PPIs are the most 
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efficacious GERD agents and that they are preferred treatment for children older than one, it is 
proposed that they will be effective treatments in infants. Health care providers have been 
recommending and prescribing PPIs for infants in an escalating amount. However, there is a 
lack of sufficient evidence and reputable randomized controlled trials that demonstrate the 
efficacy and safety of PPI use in this specific population. 
OBJECTIVE: 
The objective of this systematic review is to determine whether or not proton pump 
inhibitors are a safe and effective treatment for gastroesophageal reflux disease in infants less 
than twelve months old. 
METHODS: 
All three studies selected for this review met the following criteria. The population was 
otherwise healthy infants, including premature infants, who were less than twelve months of age. 
The interventions used in the studies were the administration of weight-based doses of proton 
pump inhibitors, namely omeprazole and lanzoprazole. The main outcomes measured were 
reduction of GERD symptoms, such as cry/fuss time, irritability, vomiting, choking, apnea, as 
well as adverse events and serious adverse events. All of these outcomes qualify as patient 
oriented evidence that matters (POEM). The studies were double blind, randomized and 
placebo-controlled. 
The author searched Ovid Medline and Cochrane Database of Systematic Reviews for 
articles and RCTs using the keywords "proton pump inhibitors" and "infants". All articles in this 
review were in English and published in peer-reviewed journals. All articles were selected based 
on importance of outcomes to the patient (POEM). Inclusion criteria were studies that were 
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randomized, controlled, prospective, based on patient oriented outcomes, and published after 
1996. Exclusion criteria were articles that were published before 1996 and articles that focused 
on patients over twelve months of age. The study perfomled by Orenstein et al took place at 16 
centers, with 8 in the United States and 8 in Poland, between the dates of June 29,2006 and May 
16, 2007. The studies performed by Moore et al and Omari et al were both conducted in 
Australia. The statistics utilized in the studies were p values, number needed to harm (NNH), 
relative risk increase (RRI), and absolute risk increase (ARl). 
OUTCOMES MEASURED: 
The outcomes addressed in the Orenstein 2009 study were responder status, adverse 
events (AE) and serious adverse events (SAE). AEs were treatment emergent cases and SAEs 
required hospitalization. Responder status is defined to be >50% reduction from baseline in 
either percentages of feedings with crying episodes or duration (in minutes) of episodes averaged 
across feedings. Responder rate was the percentage of participants who were responders at week 
4. Outcomes were measured by documenting the daily number and duration of crying episodes 
during or sl hour after feeding. AEs and SAEs were also documented. 
The outcomes addressed in the Moore 2003 study were the cry/fuss time of the infant in a 
24 hour period and the irritability of the child. The outcomes were measured by 1.) a diary in 
which the parents recorded infant behavior including crying and fussing time and 2.) a visual 
analog score 01 A) ranging from 0-10 of parental impression of the level of infant irritability. 
The outcomes addressed in the Omari 2007 study were symptom events that were 
recorded on bedside symptom charts by neonatal nursery staff. Symptom events were classified 
as vomiting, apnea, bradycardia, and behavioral changes. 
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Table 1: Demographics of included studies 
Study Type #Pt Age Inclusion Exclusion WD Intervention 
Criteria Criteria 
Orenstein Double 162 28 days Weight >2.0 kg, Use ofPPI in 64 Lansoprazole 1 x 
2009 (1) blind to <12 daily diary 30 days, use daily x 4 weeks. 
RCT months; documented ofH2 Dosages: 
pretenn crying during or antagonists in 0.2 to 0.3 
corrected within 1 hour 2: 7 days, mg/kglday for 
age 44 25% of feeds clinically infants :s 1 0 
weeks during 4 days of significant weeks of age; 
but <12 randomization disease, 1.0 to 1.5 
months despite 2:7 days of esophageal mg/kglday for 
non disease or infants >10 
pharmacologic upper GI weeks of age 
management anomaly, 
requirements 
of continuous 
tube feedings 
Moore, Double 30 3-12 History of Use ofPPI 4 Omeprazole: 
2003 (2) blind months in spilling, before Infants weighing 
RCT age irritability and recruitment, 5-10 kg were 
crying; previously history of given 10 mg 
given empirical melena or daily x 2 weeks; 
treatment for hematemesis, infants> 1 0 kg 
GERD; 24 hour medical or were given 10 
pH monitoring surgical mgBTD x 2 
reflux index (total condition weeks 
recording time other than 
with pH<4 in 24 GERD 
hours) of>5%, 
biopsy criteria for 
esophagitis 
Omari, Double 10 Preterm Preterm infants <32 weeks 0 Omeprazole 0.7 
2007 (3) blind infants, with symptoms of PMA,on mg/kg added to 2 
RCT mean GERD who did CPAP or mLlkg of antacid 
post not respond to ventilation, Mylanta given in 
menstrual conservative acute illness, NG tube to 
age of therapy, reflux neurologic infant 
36.1 index >5% disease, 
weeks, hepatic/ 
mean renal 
postnatal impainnent, 
age 50 bone marrow 
days abnormality 
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RESULTS 
The Orenstein 2009 study compared the efficacy of PPI lansoprazole versus placebo for 
the reduction of GERD symptoms as shown in Table 2. Lansoprazole and placebo produced 
identical responder numbers (54%). Both the relative benefit increase and absolute benefit 
increase are zero, which produced an unreal number for number needed to treat. Interestingly, 
responder rates were greater in patients who continued with non-pharmacological management 
into the double-blind period (63%) compared those who did not (19%). This study included 
rates for compliance with medication (93% for PPI vs. 95% for placebo) and diary recordings 
(96% PPI vs. 95% placebo). 
Table 2: Efficacy of )ansoprazo)e vs. placebo for reduction of GERD symptoms, Orenstein 2009 
Lansoprazole Placebo double- P Lansoprazole 
double-blind blind, (:54 value open label 
(:54 weeks, weeks, n=81)* (1-3 weeks, 
n=81)* n=55) * 
Primary efficacy: Responder rate, 44 (54%) 44 (54%) NS NA 
n(%) 
Discontinued due to non-efficacy, 28 (35%) 29 (36%) NS 0 
n (%) 
Compliance 
> 90% for drug, % of sub.iects 93% 95% - 98% 
2: 90% for daily diary, % of 96% 100% - 93% 
subjects 
Global Severity assessment § 
By parent: Improvement at 45 (56%) 41 (51%) NS 44 (80%) 
week 4 
By physician: improvement at 44 (55%)~ 40 (49%) NS 47 (85%) 
week 4 
Individual Symptoms 
Cry, % of feeds/ week -20 -20 NS -19 
Re2ur2itate, % of feedsl week -14 -11 NS -20 
Stop feed soon, % of -7 -8 NS -3 
feeds/week 
Feed refusal, % of days/week -14 -10 NS -15 
Archin2 back, % of day_s/week -20 -18 NS -33 
Cou2hin2, % of days/week 0 -9 NS -3 
Wheezing, % of days/week -5 -6 NS -12 
Hoarseness 2 -5 NS -9 
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NS, not significant; NA, not applicable 
*For subjects withdrawn from double-blind treatment before the 4th week, the last week of available data 
is carried forward to the 4th week for the individual symptoms and GAs. The open label treatment ranged 
from 1-3 weeks, depending on the time of withdrawal from the double-blind treatment; the final week of 
open label data is summarized. 
§Improved at least 1 severity level compared to baseline assessment 
,nata missing from 1 subject: 44/80 (54%) 
Assessing the safety of this drug class for this age group and population is a high priority 
of this systematic review. The Orenstein 2009 study demonstrated that there are some safety 
concerns, as illustrated in Table 3. There were more treatment emergent adverse events in the 
lansoprazole-treated subjects than the placebo group (62% vs. 46% respectively). Of the 
subjects who continued with open-label treatment with lansoprazole, 62% experienced AEs. 
AEs were mostly mild or moderate and include (in descending order of frequency of 
occurrence): upper respiratory infections, constipation and GERD, dermatitis and eczema, ear 
infections, fever, lower respiratory infections, respiratory tract congestion, rhinorrhea, 
candidiasis, diarrhea (excluding infective), vomiting, alkaline phosphatase increase, and viral 
infection. The p-value of 0.058 was deemed as not significant. The relative risk increase (RR!) 
and absolute risk increase (ART) were 35% and 16%, respectively. The numbers needed to harm 
(NNH) is 7. 
Serious AEs (SAEs) during the double-blind treatment were significantly more frequent 
in the lansoprazole group compared to placebo (12% vs. 2%). The p-value is 0.032 which 
indicates clinical significance. Number needed to harm is 10 patients and the RR! and ARI are 
5% and 10%, respectively. All patients with SAEs were hospitalized and no deaths occurred. 
SAEs include the following medical conditions in descending order of frequency: lower 
respiratory infections, diarrhea, ileus, dehydration, ear infection (otitis media), upper respiratory 
infections, epididymal infection, arachnoid cyst, cellulitis, febrile convulsion, and Klebsiella 
infection. Orenstein et al reported that no SAE was identified as being directly treatment-related. 
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Table 3: Adverse events of the Orenstein 2009 study comparing lansoprazole to placebo 
Lansoprazole Placebo P value* Lanzoprazole RRI ARI 
double blind double open label 
(n=81) blind (n=55) 
(n=81) 
AE collection 8.3, 1-9 8.3 , 1-9 NS 7.3, 5-8 - -
weeks, median, 
range' 
AE 50 (62%) 17 NS 11 (20%) 35% 16% 
(21%) (p=0.058) 
SAEs 10 (12%) 2 (2%) 0.032 2 (4%) 5% 10% 
NS, not significant; RRI, relative risk increase; ARl, absolute risk increase; NNH, numbers needed to 
harm 
*Double blind treatment comparisons: Fisher exact test for AE percentage; Wilcoxon test for weeks of 
AE collection 
~or the double blind period, "collection weeks" includes 30 days posttreatment for those subjects who 
did not enter open label treatment. For open label period this includes 20 days posttreatment for all 
subjects who entered open-label treatment. 
NNH 
-
7 
10 
The outcomes measures in the Moore 2003 study were cry fuss time in minutes/24 hours 
and a parental visual analog score. Results are shown in Tables 4 and 5. Period 1 and period 2 
denotes the first two weeks and second two weeks of the trial, respectively. There was no 
significant difference in the cry/fuss time while taking either omeprazole or placebo (191 vs. 
200, P=0.400), nor was there a significant difference in cry/fuss time between period 1 and 2 
(P=0.330). There was a significant decrease in cry/fuss time from baseline to period 1 (267 vs. 
203, P= 0.040) and from baseline to period 2 (267 vs. 188, P=0.008). In an analysis of treatment 
order (subjects who initiated with omeprazole vs. subjects who initiated with placebo group) 
there was no difference in cry/fuss time from baseline (P=0.481), period 1 (P=0.604), or period 2 
(P=0.534). 
The visual analog device was a double sided slide rule with the side facing the parent 
showing two extremes of "no irritability" and "worst irritability" and the side facing the 
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investigator showing a linear scale of 0 to 10. The V A score while taking omeprazole or placebo 
was not significantly different (5.0 vs. 5.9, P=0.214). While there was not a remarkable decrease 
in the V A score between baseline and period 1 or between period 1 and 2, there was a significant 
decrease between baseline and period 2 (6.8 vs. 4.8, P=0.008). In an analysis of treatment order, 
there was no significant difference in VA score from baseline (p= 0.262), period 1 (p=0.724), or 
period 2 (p=0.1 05). The data provided in Moore 2003 study is on a continuous scale and could 
not be converted dichotomously to directly answer whether or not there was a treatment effect. 
T bl 4 C fu d a e ;ry ss t t ata m response to rea ment WI b M omeprazo e or pl ace 0, 
Cry fuss time in min/24 hr (mean ± SD) 
Baseline Period 1 
Omeprazole (n=lS) 246±}05 203 ±113 
Placebo (n=lS) 287±132 204±87 
Total (n=30) 267±1l9 203±99 
*Mean of the combined data from Period 1 and Period 2 (n=30) 
Baseline vs. Period 1, P=0.040 
Baseline vs. Period 2, P=0.008 
Period 2 
179±129 
198±115 
188±121 
oore 200~ 
-' 
Combined* 
191±120 
201±100 
Table 5: Visual analog score by parents of the level of infant irritability in response to treatment 
·th 1 IbM 2003 WI omeprazo e or place 0, oore 
Visual analogue scale of infant irritability mean ± SD) 
Baseline Period 1 
Omeprazole (n=lS) 7.1±1.4 5.9 ±2.6 
Placebo (n=lS) 6.6±1.7 6.0±2.1 
Total (n=30) 6.8±1.6 6.0±2.3 
*Mean of the combined data from Period 1 and Period 2 (n=30) 
Baseline vs. Period 2, P=0.008 
Period 2 
4.0±3.3 
5.7±2.2 
4.8±2.9 
Combined* 
5.0±3.1 
5.9±2.1 
The Omari 2007 study demonstrated through esophageal pH monitoring that omeprazole 
therapy significantly reduced gastric acidity, esophageal acid exposure and the number and 
duration of acid reflux episodes compared to placeb03. However, the PPI did not demonstrate a 
significant change in the number of symptomatic events that are attributed to GER, as illustrated 
in Table 6. The treatment effect cannot be calculated based on the continuous data that was 
gIven. 
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Table 6: Effect of omeprazole on GER symptoms in preterm infants, Omari 2007 
Symptoms Frequency (number of events) 
Placebo week Omeprazole week 
Vomiting 8.5 (7,22.8) 6.5 (3, 14.3) 
Apnea 0.4 (0, 1.5) 1 (0, 1.8) 
Bradycardia 7.5 (1.3, 17.3) 6.5 (3, 16) 
Choking 0(0, 1) 0(0, 1.8) 
Behavioral changes 17 (8.3, 27.8) 16.5 (7.3,30.1) 
Data is presented as mean ± SEM or median (interquartile range). 
DISCUSSION 
Proton pump inhibitors have attained the FDA approval for children one year and older 
and adults for short term treatment of symptomatic GERD and healing and symptomatic relief of 
all grades of erosive esophagitis. The only contraindication is sensitivity to prior PPIs or any 
component of the medication. The many available forms ofPPls include as a prescription, 
generic, and over the counter medication, such as Prevacid OTe (lansoprazole). PPIs have 
recently been in the medical news for their possible interactions with clopidogrel and the 
possible increase risk of fractures of hip, wrist, and spine; however, these circumstances do not 
directly apply to a patient population of infants. Pediatric Lexicomp Online states the uses and 
possible doses of lansoprazole for infants beginning at three months of age. Most importantly, 
Lexicomp found it necessary to note that treatment of GERD in children less than twelve months 
old is controversial based on the findings of the Orenstein 2009 trial. 
There were noteworthy limitations to these studies. Firstly, crying is nonspecific to 
GERD; the coexistence of crying and reflux does not establish a causal relation. Behaviors that 
are thought to be reflux related also occur in infants independent of acid reflux episodes. 
Secondly, there may have been some variability with the outcomes data. Although all three 
studies' outcomes were concerned with the subjects' reduction of symptoms, they were 
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measured and recorded differently. It would have proven to be a more accurate comparison of 
the three studies if the outcomes were measured identically. For example, Orenstein 2009 study 
dealt with responder status and adverse events while Omari 2007 focused on symptoms observed 
and documented by nursing staff. Additionally, limitations regarding treatment could have 
included dosing, duration, or appropriate target. Orenstein 2009 study allowed subjects to enter 
an open label treatment after only one week of double blind treatment, which may have 
decreased the double blind response rate. Similarly, Omari 2007 subjects were only on the PPI 
and placebo for one week each while Moore 2005 trial lasted 4 weeks. 
Finally the Moore 2005 study suggested that infant irritability can improve with time, 
independent of treatment. For both the cry/fuss time and VA score there was a significant 
decrease between baseline and period 2. If the primary mechanism for reflux in an infant is 
transient relaxation of lower esophageal sphincter, then it would be logical to postulate that as 
the muscle tone of sphincter increases with age, the symptoms of GERD should subside. 
CONCLUSION 
Proton pump inhibitors are not a safe and effective treatment for gastroesophageal reflux 
disease in infants less than 12 months old. Although the PPIs may have reduced the gastric and 
esophageal acidity, none of the trials showed a reduction in symptoms such as crying and 
irritability. In addition, placing infants on PPIs may put them at increased risk for adverse 
events. Future trials are warranted to investigate the primary cause of reflux symptoms in 
infants. It would be interesting to perform manometry of the lower esophageal sphincter to 
determine if relaxation of the sphincter can be attributed for the reflux. Serial esophageal 
manometry could establish if the strength of the sphincter increases with age and development, 
resulting in reduction of symptoms of GERD. 
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